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Abstract
Aims/hypothesis This study aimed to determine the frequency
of residual beta cell function in individuals with long-standing
type 1 diabetes who were recruited at diagnosis, and relate this
to baseline and current islet autoantibody profile.
Methods Two hour post-meal urine C-peptide:creatinine
ratio (UCPCR) and islet autoantibodies were measured in
samples collected from 144 participants (median age at
diagnosis: 11.7 years; 47Q male), a median of 23 years
(range 12–29 years) after diagnosis. UCPCR thresholds
equivalent to mixed meal-stimulated serum C-peptide
>0.001 nmol/l, ≥0.03 nmol/l and ≥0.2 nmol/l were used to
define ‘detectable’, ‘minimal’ and ‘residual/preserved’)
endogenous insulin secretion, respectively. Autoantibodies
against GAD (GADA), islet antigen-2 (IA-2A), zinc trans-
porter 8 (ZnT8A) and insulin (IAA) were measured by
radioimmunoassay.
Results Endogenous C-peptide secretion was detectable in 51
participants (35.4Q), including residual secretion in seven
individuals (4.9Q) and minimal secretion in 14 individuals
(9.7Q). In the 132 samples collected more than 10 years after
diagnosis, 86 participants (65.2Q) had at least one islet auto-
antibody: 42 (31.8Q) were positive for GADA, 69 (52.3Q)
for IA-2A and 14 of 104 tested were positive for ZnT8A
(13.5Q). The level of UCPCR was related to age at diagnosis
(p=0.002) and was independent of diabetes duration, and
baseline or current islet autoantibody status.
Conclusions/interpretation There is evidence of ongoing
autoimmunity in the majority of individuals with longstanding
diabetes. Endogenous insulin secretion continues for many
years after diagnosis in individuals diagnosed with
autoimmune-mediated type 1 diabetes above age 5. These find-
ings suggest that some beta cells are protected from continued
autoimmune attack in longstanding type 1 diabetes.
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Introduction
In type 1 diabetes, insulin producing beta cells are targeted for
autoimmune destruction. All beta cells were formerly
assumed to be destroyed but increasing evidence now indi-
cates that endogenous insulin secretion occurs many years
after diagnosis in some individuals with type 1 diabetes
[1–4]. This phenomenon is associated with fewer complica-
tions, notably reduced incidence of severe hypoglycaemia [5].
These previous studies have been conducted on longstanding
patients, but islet autoantibodies were not tested close to
diagnosis.
The aim of this study was to determine the frequency of
residual C-peptide secretion in a cohort of patients with
longstanding type 1 diabetes in whom islet autoantibody mea-
surements were carried out within 2 years of diagnosis, to
establish whether persistent beta cell function and baseline
or current islet autoantibody status are associated.
Methods
Study population
Participants were identified from the Bart’s Oxford (BOX)
study. This is a prospective, population-based study that has
recruited families of children who developed type 1 diabetes
before the age of 21 since 1985, in the former Oxford Health
Authority Region [6]. For this sub-study, further inclusion
criteria were diagnosis between 1985 and 2003 with an islet
autoantibody positive serum sample collected within 2 years
of diagnosis.
Ethical approval was obtained from the National Research
Ethics Service (NRES) East Midlands Leicester Research
Ethics Committee (March 2012). Informed consent was
obtained from all participants and research was carried out
in accordance with the Declaration of Helsinki, as revised in
2008.
Urinary C-peptide
Participants were asked to provide a urine sample, collected in
boric acid preservative, 2 h after their main meal of the day and
to return the sample on the same day by post to the University
of Bristol (Bristol, UK) [7]. Urine samples were aliquoted on
arrival and stored at −70°C until shipped frozen by courier to
the Biochemistry Department, Royal Devon and Exeter
Hospital (Exeter, UK) where the urine C-peptide:creatinine
ratio (UCPCR) analysis was carried out.
Urine C-peptide wasmeasured by electrochemiluminescence
immunoassay as previously described [7]. The thresholds for
UCPCR were defined as detectable (>0.001 nmol/mmol),
minimal (≥0.03 nmol/mmol) and residual/preserved
(≥0.2 nmol/mmol) [8].
Islet autoantibodies
To determine current islet autoantibody status, participants
collected capillary blood at home using a standard collection
system (Microvette 200, Sarstedt, Nümbrecht, Germany) and
returned the whole blood samples by standard post, for serum
separation at the University of Bristol. These samples, along
with serum collected from the same individuals within 2 years
of diagnosis were tested for islet autoantibodies to GAD
(GADA), islet antigen-2 (IA-2A), zinc transporter 8
(ZnT8A; recognising arginine [ZnT8RA] or tryptophan
[ZnT8WA] at position 325) and insulin (IAA, tested ≤2 weeks
after diagnosis to avoid detection of antibodies to injected
insulin) using up-to-date assays [9, 10]. GADA and IA-2A
results were expressed as DK units/ml (assigned during the
NIDDK sponsored autoantibody harmonization program [9]),
whilst IAA and ZnT8A were expressed in arbitrary units
(AU), derived from standard curves. Assays showed good
performance in the Islet Autoantibody Standardization
Program workshops (data not shown), presented at the
Immunology of Diabetes Society meeting in 2012 (Victoria,
BC, Canada) and 2015 (Munich, Germany).
HLA Class II Genotyping
Mouth brush samples were genotyped for HLA class II
using PCR of sequence specific oligonucleotides. HLA
haplotypes of interest were designated as DR3-DQ2
(HLA-DRB1*03-DQA1*0501 -DQB1*0201), DR4-DQ8
(HLA-DRB1*04 -DQA1*0301 -DQB1*0302), DR15-DQ6
(HLA-DRB1*15-DQA1*01-DQB1*0602), or none of the
above (X). Genetic risk groups were defined as high
(DR3-DQ2/DR4-DQ8), moderate (DR3-DQ2/DR3-DQ2,
DR4 -DQ8 /DR4 -DQ8 , DR4 -DQ8 /X ) or low risk
(DR3-DQ2/X, X/X). Samples were also screened for the
presence of HLA-A*24, as previously described [10].
Data Analysis
Kendall rank tests (correlation coefficient, τB) were used to
compare UCPCR and autoantibody levels. Kruskall–Wallis
and Mann–Whitney U tests were used to compare continuous
variables within different categorical variables (e.g. geno-
type). χ2 analysis was used to compare persistence of islet
autoantibodies. Analysis was carried out using the Statistical
Package for the Social Sciences (SPSS), version 21 (available
from www-03.ibm.com/software/products/en/spss-statistics).
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Results
Patient Characteristics
By December 2003, 2127 individuals with longstanding dia-
betes had been recruited to the BOX study, of whom 1011 had
suitable ‘at diagnosis’ samples available. Current contact
details were available for 616 individuals and these were in-
vited to join this study. Consent was obtained from 257 indi-
viduals, to whom sample collection kits were sent. Urine sam-
ples for UCPCR were returned by 157 participants (61.1Q).
Re-testing of baseline autoantibody samples was possible for
144 (47Q male) of these participants of whom 132 returned
follow-up serum samples (Table 1). These participants were
representative of the BOX cohort for the average age at diag-
nosis and timing of initial sample for autoantibody testing,
although there was a higher proportion of female participants.
Residual C-peptide secretion
Of the 144 urine samples tested a median of 23 years after
diagnosis, 51 (35.4Q) had detectable UCPCR C-peptide;
seven individuals (4.9Q) had residual (preserved) and 14
(9.7Q) had minimal C-peptide secretion.
Levels of UCPCR were associated with age at diagnosis
(p=0.002, τB=0.198; Fig. 1a); two of 17 children (11.8Q)
diagnosed before the age of five had detectable C-peptide
(none had minimal or residual levels) compared with 49 of
127 (38.6Q) in participants diagnosed over the age of five
(p=0.030). Levels of UCPCR were not associated with dis-
ease duration (p=0.531, Fig. 1b).
Persistent autoimmunity in longstanding diabetes
Of the 132 participants with a follow-up serum sample, 102
(77.3Q) were positive for GADA and 106 (80.3Q) were pos-
itive for IA-2A at diagnosis. Of those who tested positive for
GADA and IA-2A autoantibodies, 39 (38.2Q) had persistent
GADA and 69 (65.1Q) had persistent IA-2A in the follow-up
sample a median of 23 years after diagnosis. Three partici-
pants who were GADA negative at baseline became positive
at follow-up. Of the 104 follow-up samples with sufficient
serum for ZnT8A testing, 76 (73.1Q) were positive at base-
line, of which 14 (18.4Q) had persistent ZnT8A.
Table 1 Autoantibody characteristics of participants
Baseline Follow-up
n 144 132
Male 67 (47) 59 (45)
Age at time of sample, years 11.7 (1.4–22.1) 32.9 (16.9–48.2)
Time after diagnosis, months 1.5 (−10.4–20.5) 271.8 (146.1–350.6)
Samples testing positive for islet autoantibodies:
GADA 111 (77.1) 42 (31.8)
IA-2A 115 (79.9) 69 (52.3)
ZnT8A 104 (72.2) 14 (13.5a)
IAA 43 (71.7b) NT
≥1 antibodies 144 (100.0) 86 (65.2)
≥2 antibodies 127 (88.2) 33 (25.0)
Data are presented as median (range) or n (Q)
a For the measurement of ZnT8A at baseline, n=104
b For the measurement of IAA at baseline, n=60
NT, not tested
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Fig. 1 Association between UCPCR and (a) age at diagnosis, (b) dura-
tion of disease (c, e, g) autoantibody levels at diagnosis or (d, f, h) at time
of UCPCR measurement. For (g) and (h) black circles, ZnT8RA; white
circles, ZnT8WA. Detectable C-peptide is shown >zero nmol/mmol.
Dotted lines show minimal (0.03 nmol/mmol) and residual (0.2 nmol/
mmol) C-peptide levels. Dashed lines show autoantibody positivity
thresholds: GADA, 33 DK units/ml; IA-2A, 1.4 DK units/ml; ZnT8A,
1.8 AU
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Persistent IA-2Awas more common in males than females
(77Q vs 56Q, p=0.031), while both IA-2A (median 9.1 vs
12.0 years, p<0.005) and ZnT8A (median 11.0 vs 15.9 years,
p=0.030) were associated with an older age at diagnosis.
Antibody positivity and C-peptide
There was no association between levels of UCPCR and
GADA (p = 0.532, Fig. 1c), IA-2A (p = 0.132, Fig. 1e),
ZnT8RA and ZnT8WA (p=0.292 and p=0.894, respectively,
Fig. 1g), or IAA (p=0.076, data not shown) at diagnosis.
Levels of UCPCR were weakly correlated with persistent
GADA (p = 0.045, τB = 0.136, Fig. 1d) but not IA-2A
(p=0.579, Fig. 1f) or ZnT8RA and ZnT8WA (p=0.660 and
p=0.581, respectively, Fig. 1h). Of those with residual beta
cell function, five of seven were islet autoantibody negative.
Residual beta cell function and HLA genotype
There was no association between HLA Class II risk (high,
moderate or low) or HLA-A*24 and UCPCR level (p=0.696
and p=0.942, data not shown).
Discussion
We have shown that residual endogenous insulin secretion and
persistent autoimmunity occur more than a decade after diag-
nosis in patients with proven autoimmune-mediated type 1
diabetes. Preservation of C-peptide was associated with age
at diagnosis but not with disease duration; none of those diag-
nosed before the age of 5 years had residual beta cell function
(equivalent to stimulated serum C-peptide more than
0.2 nmol/l) compared with a fifth of those diagnosed after this
age. However, no correlation was found between C-peptide
and persistent autoimmunity.
This is the first study to investigate endogenous insulin
secretion in longstanding diabetes using islet autoantibody
data at time of diagnosis. Up-to-date assays were used to test
144 historical and current samples for UCPCR and for islet
autoantibody (GADA, IA-2A, ZnT8A) status. Additionally,
IAA was measured but, since most samples were taken after
insulin treatment had begun, these autoantibodies were only
tested in 60 participants at baseline. Ongoing islet autoimmu-
nity was evident in >60Q of participants, with particular
persistence of IA-2A. The reason why some individuals
remain islet autoantibody positive for decades while others
do not, is partly related to age at onset of diabetes and sex.
Of seven individuals with residual beta cell function, five
had no evidence of ongoing islet autoimmunity. Correlation of
C-peptide levels with current GADA levels only achieved
borderline statistical significance. Overall, we did not see a
strong relationship between baseline autoantibody responses
and persistence of beta cell function. A larger longitudinal
study is required to investigate this further.
A recent study by Oram and colleagues [8], used the same
UCPCR assay as that used in this study to report that 740 of 924
(80Q) participants in a cross-sectional study had detectable
levels of exogenous C-peptide, a median of 19 years from di-
agnosis. This is more than double the frequency of detectable
C-peptide observed in our study. While the participants in our
study had confirmed type 1 diabetes at diagnosis, this does not
account for the large disparity in findings. Despite looking
closely at the participant characteristics and sample collection
protocols for each study, an explanation for the difference be-
tween the studies could not be identified. Data were not avail-
able from this study to examine whether detectable C peptide
secretion is associated with improved glycaemic control. The
finding of detectable C-peptide and persistent islet autoimmu-
nity supports histological observations of intact beta cells in the
pancreas from individuals with longstanding type 1 diabetes
[1]. The presence of functioning beta cells years after diagnosis,
and the strong association between age at diagnosis and endog-
enous insulin secretion suggest that, compared with those who
have later onset of the disease, the aggressive autoimmune re-
sponse associated with early onset type 1 diabetes may be more
difficult to regulate, resulting in complete beta cell destruction.
Intrinsic differences in immune function of those with measur-
able beta cell function, compared with those without is worthy
of further analysis. It might be postulated that those with resid-
ual beta cell function have more effective T cell regulation.
In summary, these findings demonstrate that, in longstanding
type 1 diabetes, there is evidence of ongoing autoimmunity in
the majority of individuals. However, in some (particularly
in individuals diagnosed above age 5), endogenous insulin
secretion may continue for years after diagnosis, indicating
that some beta cells may be protected from continued au-
toimmune attack.
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